Soheil Meshinchi, MD, PhD

Professional History

Board Certified:

Pediatric Hematology-Oncology

Medical/Professional School:

Wayne State University School of Medicine, Detroit

Fellowship:

Johns Hopkins Hospitals, Baltimore, Pediatrics
University of Washington School of Medicine, Seattle, Pediatric Hematology-Oncology

Research Focus Area:

Cancer

Description of Research:

My clinical and research interests center around the treatment of pediatric myeloid leukemia. I am principal investigator on six research projects at Seattle Children's and Fred Hutchinson Cancer Research Center, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification.

Key Publications:

Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, Lange BJ, Woods WG, Arceci RJ, Smith FO. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children?s Oncology Group studies CCG-2891 and CCG-2961. Blood. Mar 2007;109(6):2314?2321.

Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. Aug 2007;110(3):979?985.

Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist. Mar 2007;12(3):341?355.